This content is from:xinyabo体育app
2016 All-Asia Research Team: Health Care & Pharmaceuticals, No. 2: Qiyong (Jack) Hu & team
After two years as a runner-up, Deutsche Bank captures its first top-three finish on this lineup, leaping to second place.
Total Appearances: 4
Team Debut: 2012
After two years as a runner-up, Deutsche Bank captures its first top-three finish on this lineup, leaping to second place.Qiyong (Jack) Huleads the firm’s team of seven regional health care analysts in their reporting on 66 companies, which one investor deems always prompt and “value adding.” They are advising clients that shares in China “will be volatile in the near term, due to policy headwinds, including pricing pressure, as well as other initiatives from health care reform,” says Hu, “such as the implementation of the two-invoices mechanism,” which aims to cut out middlemen in the distribution of drugs between manufacturers and medical facilities. Going forward, “we remain constructive on the mid- and long-term growth prospects for the sector and believe near-term volatility will create buying opportunities for higher-quality names,” he advises. Hu received a Ph.D. from the University of Texas M.D. Anderson Cancer Center and began his career as an oncology marketing manager at pharmaceuticals giant Wyeth (now part of Pfizer) in Philadelphia. After three years he moved to Wall Street, starting as a biotechnology associate at Leerink Partners and later covering the U.S. sector for Oppenheimer. He soon jumped to health care hedge fund Visium Asset Management to run its Asia book in New York then returned to Asia in June 2010, signing on with Deutsche to report on regional health care names. Hu is stationed in Hong Kong and has teammates in Bangkok, Jakarta, Mumbai, Singapore, Sydney and Wellington.